These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 15625429)
1. A home infliximab infusion program. Condino AA; Fidanza S; Hoffenberg EJ J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429 [TBL] [Abstract][Full Text] [Related]
2. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease. Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062 [TBL] [Abstract][Full Text] [Related]
3. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395 [TBL] [Abstract][Full Text] [Related]
4. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. Friesen CA; Calabro C; Christenson K; Carpenter E; Welchert E; Daniel JF; Haslag S; Roberts CC J Pediatr Gastroenterol Nutr; 2004 Sep; 39(3):265-9. PubMed ID: 15319627 [TBL] [Abstract][Full Text] [Related]
5. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease. Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258 [TBL] [Abstract][Full Text] [Related]
6. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases. Saxena P; Chen G; Jideh B; Collins G; Leong RW Expert Opin Biol Ther; 2014 Mar; 14(3):277-82. PubMed ID: 24359522 [TBL] [Abstract][Full Text] [Related]
7. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases. Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731 [TBL] [Abstract][Full Text] [Related]
8. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease. Gupta SR; Crandall WV; Donegan A; Johnson M; Drobnic B; Oates M; Boyle B; Maltz RM; Dotson JL J Pediatr Gastroenterol Nutr; 2019 Nov; 69(5):544-550. PubMed ID: 31219936 [TBL] [Abstract][Full Text] [Related]
9. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions. Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840 [TBL] [Abstract][Full Text] [Related]
10. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease. Qazi T; Shah B; El-Dib M; Farraye FA Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281 [TBL] [Abstract][Full Text] [Related]
11. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
13. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Stephens MC; Shepanski MA; Mamula P; Markowitz JE; Brown KA; Baldassano RN Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944 [TBL] [Abstract][Full Text] [Related]
14. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting. Afzali A; Ogden K; Friedman ML; Chao J; Wang A J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566 [TBL] [Abstract][Full Text] [Related]
16. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465 [TBL] [Abstract][Full Text] [Related]
17. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. de Ridder L; Escher JC; Bouquet J; Schweizer JJ; Rings EH; Tolboom JJ; Houwen RH; Norbruis OF; Derkx BH; Taminiau JA J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):46-52. PubMed ID: 15187780 [TBL] [Abstract][Full Text] [Related]
18. Use of infliximab in pediatric patients with inflammatory bowel disease. Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127 [TBL] [Abstract][Full Text] [Related]
19. Safety of infliximab in Crohn's disease: a large single-center experience. Hamzaoglu H; Cooper J; Alsahli M; Falchuk KR; Peppercorn MA; Farrell RJ Inflamm Bowel Dis; 2010 Dec; 16(12):2109-16. PubMed ID: 20848473 [TBL] [Abstract][Full Text] [Related]
20. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Crandall WV; Mackner LM Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]